GAITHERSBURG, Md., March 2, 2016 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) will report financial results for the fourth quarter and year ended December 31, 2015 on Wednesday, March 9, 2016, before the U.S. financial markets open.
The company's press release will be followed by a webcast conference call at 10:00 a.m. EST to discuss GenVec's fourth quarter and 2015 financial results and 2016 business outlook. To listen to the live conference call, please dial 1-877-407-4019 (U.S. or Canada) or +1 201-689-8337 (international). An audio replay of the conference call will be available starting at 1:00 p.m. EST on March 9, 2016 through March 16, 2016. To listen to the audio replay, dial 1-877-660-6853 or +1 201-612-7415 (international) and use access code 13630958.
A live webcast of the conference call will be available on the company's website and will be archived for 90 days. To access the webcast or the replay, go to www.genvec.com, click on the Media tab, and select Presentations from the drop-down menu.
GenVec is a clinical-stage gene delivery company focused on developing a pipeline of cutting-edge therapeutics and vaccines using its proprietary AdenoVerse™ gene delivery platform. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to its internal and partnered pipeline, the company is also focused on opportunities to license its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Contact: GenVec, Inc. Rena Cohen (240) 632-5501 firstname.lastname@example.org
SOURCE GenVec, Inc.